Entacapone is a COMT inhibitor approved for the treatment of Parkinson’s disease, in a recent study entacapone (up to 2000 mg/day) was given to 36 patients with cannabis dependence (DSM-IV) in an open-label trial for 12 weeks, continued for 12 months in interested individuals. Entacapone both short-term and long-term significantly decreased craving for cannabis in 52.7% of the patients, but no information was reported on patients’ cannabis use. Entacapone was well tolerated and there was no serious adverse event [67].
